The US-based company known as MSD outside the US and Canada announced results of the phase 3 KEYNOTE-177 trial at this year’s American Society of Clinical Oncology (ASCO) conference.

Grade 3 or 4 treatment-related adverse events (TRAE) occurred in 32% of patients. 5 Pembrolizumab was subsequently investigated in the 1L setting through the KEYNOTE-177 trial, comparing it with ...

Boston Scientific is keeping the ball rolling in pulsed field ablation, posting 177% electrophysiology growth in the third quarter powered by the launch of its Farapulse system for atrial ...

Former AFN president Julie Kitka, who retired last month after more than 30 years heading the organization, delivered the keynote address. In keeping with this year’s convention theme —“Our ...

Read more about Op-Ed: I Finally Upgraded from an iPhone 6 Plus to an 8 Plus; Here's What Surprised Me Most ...

And that would be the seven-year, $177 million contract they inked with shortstop Dansby Swanson in 2022. “Dansby Swanson is neither the only player nor the worst player the Cubs have signed ...

Nvidia's CEO Jensen Huang will be appearing at CES 2025 to deliver an official keynote on January 6. While the focus is expected to be AI, rumors online also point toward a possible RTX 50 series ...

(Image: Bruce Power) In October 2022, Bruce Power became the first commercial nuclear operator to produce lutetium-177 (Lu-177), used in targeted radionuclide therapy to treat cancers like ...

Lutetium-177 (Lu-177) is a beta-emitting radioisotope used in targeted radionuclide therapy for the treatment of prostate and other cancers, destroying the cancer cells while leaving healthy cells ...